Our meetings provide a national forum for leaders in the field to explore and discuss priorities, challenges, and policy implications in health security.
Chapter One: Introduction
How FDA and other US government officials convey information about medical countermeasures (MCMs) will affect uptake, compliance, and ultimately survival in the aftermath of a natural disease emergency or a chemical, biological, radiological, or nuclear (CBRN) attack. Moreover, effective communication regarding MCMs has the potential to strengthen psychological resilience as well as engender public trust in science, government, and public health. The purpose of this casebook is to provide FDA and other officials who deliver public health information with “real world” inspired opportunities for reflective learning on the principles of effective MCM communication and on the wider contexts that influence the development, delivery, and consumption of accurate, timely, and meaningful MCM information in an emergency. Communication successes will better enable FDA to fulfill its regulatory role and activities and “facilitate the development of and access to safe, effective, and quality MCMs” to counter CBRN and emerging infectious disease threats (for more on FDA’s MCM-related mission, activities, and collaborators, see Appendix A). READ FULL CHAPTER